Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.12 +0.00%

+$0.00 today

Market cap
$605.45M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 0.84M

Average 0.54M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$155.60M

FY 2025 · Annual

Net Income

-$137.95M

FY 2025 · Annual

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development31.31M30.62M63.62M125.1M
Selling, General & Admin6.34M9.27M18.77M30.51M
Operating Expenses37.66M39.89M82.39M155.6M
Depreciation & Amortization10K19K56K105K
EBITDA(37.72M)(51.96M)(67.75M)(137.63M)
EBITDA Margin————
Operating Income(37.66M)(39.89M)(82.39M)(155.6M)
Operating Margin————
Interest Income4K1.31M14.58M17.87M
Interest Expense112K000
Other Income / Expenses(188K)(12.09M)14.58M17.87M
Income Before Tax(37.84M)(51.98M)(67.81M)(137.73M)
Pre-Tax Margin————
Income Tax Expense1K5K187K217K
Net Income(37.85M)(51.99M)(68M)(137.95M)
Net Margin————
EPS (Basic)(0.73)(1.00)(1.25)(2.52)
EPS (Diluted)(0.73)(1.00)(1.25)(2.52)
Weighted Avg Shares51.76M51.76M54.42M54.68M
Weighted Avg Shares (Diluted)51.76M51.76M54.42M54.68M

BCAX Earnings Waterfall · TTM

NASDAQ:BCAX · Revenue to Net Income

Key Ratios

EPS$-2.78
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.5
P/S Ratio0.0

Analysis

$0 of revenue converted into -$157.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.78, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingNov 10, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13G/ASC 13G/A filingOct 7, 2026
4Statement of changes in beneficial ownershipSep 10, 2026

How much revenue does BCAX generate?

Bicara Therapeutics Inc. Common Stock (BCAX) reported $0.00 of revenue in fiscal 2025.

Is BCAX profitable?

Bicara Therapeutics Inc. Common Stock (BCAX) reported -$137.95M of net income.